Sana Biotechnology, Inc. (NASDAQ:SANA) Insider Sells $1,888,018.88 in Stock

Sana Biotechnology, Inc. (NASDAQ:SANA) insider Fmr Llc sold 290,912 shares of the firm’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total value of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at approximately $29,474,406.39. This represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Sana Biotechnology Stock Down 14.9 %

NASDAQ SANA opened at $3.66 on Friday. Sana Biotechnology, Inc. has a 52 week low of $1.52 and a 52 week high of $12.00. The firm has a 50 day moving average of $2.40 and a two-hundred day moving average of $4.05. The stock has a market capitalization of $817.16 million, a PE ratio of -2.61 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. On average, equities research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on SANA shares. TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday. JMP Securities cut shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. Finally, HC Wainwright upped their price objective on Sana Biotechnology from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Sana Biotechnology has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.

Institutional Investors Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB purchased a new position in shares of Sana Biotechnology during the third quarter worth about $29,000. Stifel Financial Corp purchased a new position in Sana Biotechnology during the 3rd quarter worth approximately $43,000. EP Wealth Advisors LLC acquired a new position in Sana Biotechnology during the third quarter worth approximately $45,000. Blue Trust Inc. lifted its stake in Sana Biotechnology by 1,246.6% in the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after buying an additional 12,154 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new stake in shares of Sana Biotechnology in the third quarter valued at approximately $67,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.